These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 24033253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB, Coyne DW.
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B, Mariusz S, Jacek R.
    Curr Pharm Biotechnol; 2017 Nov; 18(4):303-308. PubMed ID: 28137221
    [Abstract] [Full Text] [Related]

  • 8. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
    [Abstract] [Full Text] [Related]

  • 9. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [Abstract] [Full Text] [Related]

  • 10. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA, TREAT Executive Committee.
    N Engl J Med; 2007 Mar 01; 356(9):959-61. PubMed ID: 17329707
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
    Agarwal AK.
    Expert Opin Drug Saf; 2009 Mar 01; 8(2):145-53. PubMed ID: 19309243
    [Abstract] [Full Text] [Related]

  • 14. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
    Milovanov IuS, Milovanova LIu.
    Ter Arkh; 2012 Mar 01; 84(6):48-52. PubMed ID: 22997919
    [Abstract] [Full Text] [Related]

  • 15. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
    Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S.
    Kidney Int; 2014 Jul 01; 86(1):34-9. PubMed ID: 24402094
    [Abstract] [Full Text] [Related]

  • 16. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB, ESA Clinic Study Group.
    Am J Kidney Dis; 2012 Sep 01; 60(3):371-9. PubMed ID: 22633556
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Erythropoietin and resistant hypertension in CKD.
    Boyle SM, Berns JS.
    Semin Nephrol; 2014 Sep 01; 34(5):540-9. PubMed ID: 25416663
    [Abstract] [Full Text] [Related]

  • 19. [Role of renal anemia in progression of chronic kidney disease].
    Racki S, Maleta I.
    Acta Med Croatica; 2009 Sep 01; 63 Suppl 1():33-7. PubMed ID: 20235353
    [Abstract] [Full Text] [Related]

  • 20. New Treatment Approaches for the Anemia of CKD.
    Bonomini M, Del Vecchio L, Sirolli V, Locatelli F.
    Am J Kidney Dis; 2016 Jan 01; 67(1):133-42. PubMed ID: 26372086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.